Respiratory
Respiratory is entering its own wave of biologic and inhaled-therapy differentiation. As targeted therapies reshape severe asthma and COPD management, knowing where prescriber sentiment is heading, before it shows up in share data, is what separates brands that win market position from brands that defend it.
Subscribe for Respiratory updates
About Respiratory
Respiratory care is undergoing rapid change as biologic therapies for asthma and emerging inhaled and biologic options for COPD compete for physician attention alongside long-established standards of care. Interstitial lung disease is seeing similar shifts, as new treatment options enter the market while significant unmet need persists across patient populations. With payers tightening step-edit and prior-authorization policies even as new entrants expand the treatment landscape, the gap between what physicians say they prescribe and what is driving their decisions has never been more commercially consequential.
INDICATIONS COVERED
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Interstitial Lung Disease (ILD)
Spherix has tracked respiratory for 2 years and is launching respiratory coverage in 2026, working with leading and emerging biopharma companies and investment firms shaping innovation in the category. Our respiratory research capabilities provide reliable access to qualified allergists/immunologists and pulmonologists across the U.S. and EU through the Spherix community, targeted specialist outreach, and a network of trusted recruitment partners. This reach is demonstrated by 15+ consecutive months of successful monthly respiratory research, consistently meeting quotas of 50+ U.S. allergists, with recruitment tailored by therapeutic focus, practice setting, patient population, and study requirements. Spherix has also published 6 respiratory-focused reports this year, including research in asthma and COPD across physician and payer audiences, with more patient perspectives on the horizon.
The insights that inform confident, strategic decisions
The Spherix three-perspective lens applied to respiratory:
physician
How are pulmonologists and allergists sequencing inhaled and biologic therapies as the asthma class matures? Where is prescriber intent shifting in COPD as triple-therapy inhalers and new mechanisms arrive?
Patient
Where do patient and physician views on symptom control, exacerbation risk, burden and unmet needs diverge in asthma and COPD? What does the overall patient journey look like and how does it change for different patients?
payer (market access)
How are payers managing the cost curve as the inhaled and biologic classes in asthma expand? Where are step-edit and prior-authorization policies tightening for both biologics and inhaled combination therapies in COPD?
Spherix clients have exclusive access to
Research products
Therapeutic expertise and advisory
Customization and targeting
AI-assisted synthesis
Related Articles
Meet the Team
